OURANIA WALRAVEN: Open Payments
NPI 1992825632 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,057 in 93 payments from 16 companies in 2025. Trend: 2023 $1,470 · 2024 $1,914 · 2025 $2,057
Food & beverage: $2,057
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 25 | $385 |
| Alnylam Pharmaceuticals Inc. | 9 | $256 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $248 |
| AstraZeneca Pharmaceuticals LP | 11 | $229 |
| Abbott Laboratories | 9 | $183 |
| Merck Sharp & Dohme LLC | 8 | $162 |
| BridgeBio Pharma, Inc. | 6 | $154 |
| CVRx, Inc. | 2 | $110 |
| Kestra Medical Technology Services, Inc. | 2 | $88 |
| SCPHARMACEUTICALS INC. | 2 | $72 |
Products named: LEQVIO, AMVUTTRA, JARDIANCE, WAINUA, Attruby, CARDIOMEMS, VERQUVO, Barostim Neo System.
Industry payments across NY — which companies pay providers there.
